Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's CRO Industry Pulling Out All Stops In The Year Of The Tiger (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - By the end of 2009 there were roughly 500 contract research organizations in China, most of which are small registration consultants, and about 150 execute research work. Driven by the trend to offshore R&D work from big pharmas and the double digital growth of the Chinese market, the number of CRO companies is expected to increase further and offer broader services in the upcoming Chinese Year of The Tiger

You may also be interested in...



Pharmaron Acquires Bridge China To Become Fully-integrated CRO

SHANGHAI - Pharmaron, a Beijing-headquartered contact research organization, announced Jan. 11 that it has acquired Bridge Laboratories China, a leading preclinical CRO in China, to add toxicology services to its portfolio

Pharmaron Acquires Bridge China To Become Fully-integrated CRO

SHANGHAI - Pharmaron, a Beijing-headquartered contact research organization, announced Jan. 11 that it has acquired Bridge Laboratories China, a leading preclinical CRO in China, to add toxicology services to its portfolio

Wuxi And Qiagen Form Biomarker Partnership In Shanghai

SHANGHAI - WuXi Pharmatech, China's top contract research organization, and Qiagen, the leading global provider of sample and assay technologies, announced Jan. 11 that they reached an agreement to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets for their respective client bases

Related Content

Latest News
UsernamePublicRestriction

Register

SC073178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel